Developer docs
API playgroundTry for free, no card

Search company profiles

Lyra Therapeutics

Full company profile

uuid0002afb

Namestring
Lyra Therapeutics
Legal namestring
Lyra Therapeutics, Inc.
Company typeenum
Public
Founded yearint
2015
Operating statusenum
Closed
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersWatertown, United States
HQ citystring
Watertown
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
chronic rhinosinusitis treatment, sinonasal drug delivery, bioabsorbable nasal mesh, drug-device combination products, localized anti-inflammatory therapy
Industry2 codes
PRIMARYHLAHAIAK
Nasal Drug Delivery Devices (Sprays/Powder Devices)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Drug Delivery Devices (Injectors, Pumps, Inhalers)
SECONDARYHLAKAMAD
Rhinology & Sinus Surgery
NAICS code1 code
  • Scientific Research and Development Services5417
SIC code1 code
  • Surgical & Medical Instruments & Apparatus3841
Product category
ENT Therapeutics
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Pharmaceutical product sales
TypeOne Time License
Description

Pre-revenue clinical-stage biotechnology company developing biopharmaceutical products (LYR-210 and LYR-220) for chronic rhinosinusitis. Future revenue expected from product commercialization following FDA approval.

lyratherapeutics.com
2NDA submission and commercialization
TypeOne Time License
Description

Company completed ENLIGHTEN 2 Phase 3 trial and intends to seek NDA submission for LYR-210 for treatment of chronic rhinosinusitis

investors.lyratherapeutics.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure, Others
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Lyra Therapeutics develops bioabsorbable drug-eluting nasal mesh products (LYR-210 and LYR-220) built on its proprietary XTreo™ platform to deliver up to six months of continuous mometasone furoate anti-inflammatory therapy directly to sinonasal tissues. The products are designed for single in-office administration by ENT specialists to treat adult chronic rhinosinusitis (CRS) patients who have either failed current medical management (LYR-210) or have persistent disease after prior sinus surgery (LYR-220).

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • 14 million CRS patients in US; 4 million fail medical management
+2 more records
Product overview1 text field

Lyra Therapeutics is a clinical-stage biotechnology company with two bioabsorbable nasal mesh product candidates built on its proprietary XTreo™ drug delivery platform. Lead product LYR-210 (Phase 3) targets surgically-naïve CRS patients without nasal polyps, while second product LYR-220 (Phase 2 completed) is sized for CRS patients with post-surgical anatomy. Both products deliver continuous mometasone furoate anti-inflammatory therapy for up to six months via a single in-office administration, addressing the treatment gap for the approximately 4 million CRS patients who fail medical management.

Product and service2 records
1LYR-210
CategoryENT Therapeutics / Drug-Device Combination Product
Description

Bioabsorbable nasal mesh designed to deliver up to six months of continuous mometasone furoate anti-inflammatory therapy to sinonasal passages for treatment of chronic rhinosinusitis (CRS) in adult patients who have failed current medical management. Administered via brief in-office procedure by ENT specialists. Was in Phase 3 ENLIGHTEN clinical development.

2LYR-220
CategoryENT Therapeutics / Drug-Device Combination Product
Description

Bioabsorbable nasal mesh (larger than LYR-210) designed to deliver up to six months of continuous mometasone furoate anti-inflammatory therapy for CRS patients with post-surgical anatomy (enlarged nasal cavity after prior sinus surgery). Administered via brief in-office procedure by ENT specialists. Completed Phase 2 BEACON trial.

Scale indicator11 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
1RVAC Medicines
Strategic tierMinorTypeOthers
Description

RVAC Medicines (US), Inc. is the sublandlord for Lyra's office space at 880 Winter Street in Waltham, Massachusetts. Lyra received a default notice from RVAC regarding $484,431.92 in unpaid rent and agreed to a $2.1 million termination payment to end the sublease.

biospace.com
Recent move10 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers8 records
TypeDirect peer
Description

Acquired by Medtronic in 2022, Intersect ENT developed PROPEL steroid-eluting sinus implants used by ENTs after sinus surgery. Directly comparable to Lyra's LYR-220, which targets the post-surgical CRS population with a bioabsorbable, drug-eluting nasal mesh delivering mometasone furoate.

TypeBroad incumbent
Description

GSK markets Nasonex (mometasone furoate monohydrate) — the same off-patent corticosteroid used in Lyra's LYR-210/LYR-220. As a broad respiratory/ENT incumbent, GSK represents the entrenched mometasone spray baseline against which Lyra's sustained-release implant must demonstrate superiority.

TypeDirect peer
Description

OptiNose develops nasal drug delivery products for ENT and respiratory conditions using its own Exhalation Delivery Systems platform. Like Lyra, it focuses on delivering proven drugs via novel nasal devices for chronic ENT/rhinosinusitis patients, and historically served as a direct competitor in targeted nasal delivery for CRS and related indications.

TypeBroad incumbent
Description

AstraZeneca markets Fasenra (benralizumab), a biologic approved for severe eosinophilic asthma with ongoing development in CRSwNP. As a broad respiratory player, AZ represents a major competitor and potential strategic acquirer of any late-stage CRS asset like Lyra's.

TypeOthers
Description

Nemera is a contract developer and manufacturer of nasal and pulmonary drug delivery devices, including unit-dose and multi-dose nasal spray pumps. It is a relevant ecosystem peer given Lyra's reliance on novel nasal mesh device manufacturing and supply chain know-how.

TypeEmerging player
Description

Ocular Therapeutix develops bioabsorbable hydrogel-based implants for sustained ocular drug delivery — same drug-device combination product paradigm that Lyra's XTreo mesh platform employs, just applied to a different anatomical site. Comparable technology category with similar regulatory pathway as a drug-device combination.

TypeBroad incumbent
Description

Sanofi and Regeneron co-developed Dupixent (dupilumab), the first biologic approved for inadequately controlled CRS with nasal polyps — the same surgically-naïve CRS population Lyra's LYR-210 targets. Dupixent's biologic approval defines the competitive frontier for any new CRS therapy and is the most credible substitute for procedural implants.

8Allakos
TypeEmerging player
Description

Allakos is a clinical-stage biotech developing therapeutics for inflammatory diseases including CRS with nasal polyps (CRSwNP). It targets a partially overlapping CRS subpopulation using a different mechanism (anti-Siglec-8 antibody lirentelimab), competing for the same severe CRS treatment paradigm that Lyra's LYR-210 aims to serve.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles11 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds11 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors16 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Lyra Therapeutics

ENT Therapeuticslyratherapeutics.com

Lyra Therapeutics firmographics

Firmographics
Name
Lyra Therapeutics
Legal name
Lyra Therapeutics, Inc.
Website
https://lyratherapeutics.com
Company type
Public
Founded year
2015
Operating status
Closed
Headcount range
11–50 employees
Ownership category
akta.pro rank

Lyra Therapeutics industry classification

Industry
Product category
ENT Therapeutics
NAICS
Scientific Research and Development Services (5417)
SIC
Surgical & Medical Instruments & Apparatus (3841)
akta.pro industry
PRIMARYHLAHAIAK
Nasal Drug Delivery Devices (Sprays/Powder Devices)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Drug Delivery Devices (Injectors, Pumps, Inhalers)
SECONDARYHLAKAMAD
Rhinology & Sinus Surgery

Keywords

  • Chronic rhinosinusitis treatment
  • Sinonasal drug delivery
  • Bioabsorbable nasal mesh
  • Drug-device combination products
  • Localized anti-inflammatory therapy

Where Lyra Therapeutics is headquartered

Location

Headquarters

HQ city
Watertown
HQ country
United States
HQ region
North America

Offices2 records

Markets served

Lyra Therapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure, Others

Revenue model

  1. Pharmaceutical product sales: Pre-revenue clinical-stage biotechnology company developing biopharmaceutical products (LYR-210 and LYR-220) for chronic rhinosinusitis. Future revenue expected from product commercialization following FDA approval.
  2. NDA submission and commercialization: Company completed ENLIGHTEN 2 Phase 3 trial and intends to seek NDA submission for LYR-210 for treatment of chronic rhinosinusitis

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Lyra Therapeutics product offering

Product offering

Core offering

Lyra Therapeutics develops bioabsorbable drug-eluting nasal mesh products (LYR-210 and LYR-220) built on its proprietary XTreo™ platform to deliver up to six months of continuous mometasone furoate anti-inflammatory therapy directly to sinonasal tissues. The products are designed for single in-office administration by ENT specialists to treat adult chronic rhinosinusitis (CRS) patients who have either failed current medical management (LYR-210) or have persistent disease after prior sinus surgery (LYR-220).

Product overview

Lyra Therapeutics is a clinical-stage biotechnology company with two bioabsorbable nasal mesh product candidates built on its proprietary XTreo™ drug delivery platform. Lead product LYR-210 (Phase 3) targets surgically-naïve CRS patients without nasal polyps, while second product LYR-220 (Phase 2 completed) is sized for CRS patients with post-surgical anatomy. Both products deliver continuous mometasone furoate anti-inflammatory therapy for up to six months via a single in-office administration, addressing the treatment gap for the approximately 4 million CRS patients who fail medical management.

Differentiator

Problem solved

Functional benefit

Products and services

  • LYR-210 Bioabsorbable nasal mesh designed to deliver up to six months of continuous mometasone furoate anti-inflammatory therapy to sinonasal passages for treatment of chronic rhinosinusitis (CRS) in adult patients who have failed current medical management. Administered via brief in-office procedure by ENT specialists. Was in Phase 3 ENLIGHTEN clinical development.
  • LYR-220 Bioabsorbable nasal mesh (larger than LYR-210) designed to deliver up to six months of continuous mometasone furoate anti-inflammatory therapy for CRS patients with post-surgical anatomy (enlarged nasal cavity after prior sinus surgery). Administered via brief in-office procedure by ENT specialists. Completed Phase 2 BEACON trial.

Quantifiable outcome

  • 14 million CRS patients in US; 4 million fail medical management
  • +2 more outcomes

Companies that use Lyra Therapeutics

Customer profile

Named customers1 record

Segments2 records

Ideal customer profiles1 record

Lyra Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Lyra Therapeutics partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • RVAC MedicinesminorOthersRVAC Medicines (US), Inc. is the sublandlord for Lyra's office space at 880 Winter Street in Waltham, Massachusetts. Lyra received a default notice from RVAC regarding $484,431.92 in unpaid rent and agreed to a $2.1 million termination payment to end the sublease.

Scale indicators11 records

Recent moves10 records

Expansion highlights4 records

Lyra Therapeutics competitors and assessment

Company assessment

Direct peers

  • Intersect ENT (Medtronic): Acquired by Medtronic in 2022, Intersect ENT developed PROPEL steroid-eluting sinus implants used by ENTs after sinus surgery. Directly comparable to Lyra's LYR-220, which targets the post-surgical CRS population with a bioabsorbable, drug-eluting nasal mesh delivering mometasone furoate.
  • OptiNose: OptiNose develops nasal drug delivery products for ENT and respiratory conditions using its own Exhalation Delivery Systems platform. Like Lyra, it focuses on delivering proven drugs via novel nasal devices for chronic ENT/rhinosinusitis patients, and historically served as a direct competitor in targeted nasal delivery for CRS and related indications.

Broad incumbents

  • GlaxoSmithKline: GSK markets Nasonex (mometasone furoate monohydrate) — the same off-patent corticosteroid used in Lyra's LYR-210/LYR-220. As a broad respiratory/ENT incumbent, GSK represents the entrenched mometasone spray baseline against which Lyra's sustained-release implant must demonstrate superiority.
  • AstraZeneca: AstraZeneca markets Fasenra (benralizumab), a biologic approved for severe eosinophilic asthma with ongoing development in CRSwNP. As a broad respiratory player, AZ represents a major competitor and potential strategic acquirer of any late-stage CRS asset like Lyra's.
  • Sanofi / Regeneron: Sanofi and Regeneron co-developed Dupixent (dupilumab), the first biologic approved for inadequately controlled CRS with nasal polyps — the same surgically-naïve CRS population Lyra's LYR-210 targets. Dupixent's biologic approval defines the competitive frontier for any new CRS therapy and is the most credible substitute for procedural implants.

Others

  • Nemera: Nemera is a contract developer and manufacturer of nasal and pulmonary drug delivery devices, including unit-dose and multi-dose nasal spray pumps. It is a relevant ecosystem peer given Lyra's reliance on novel nasal mesh device manufacturing and supply chain know-how.

Emerging players

  • Ocular Therapeutix: Ocular Therapeutix develops bioabsorbable hydrogel-based implants for sustained ocular drug delivery — same drug-device combination product paradigm that Lyra's XTreo mesh platform employs, just applied to a different anatomical site. Comparable technology category with similar regulatory pathway as a drug-device combination.
  • Allakos: Allakos is a clinical-stage biotech developing therapeutics for inflammatory diseases including CRS with nasal polyps (CRSwNP). It targets a partially overlapping CRS subpopulation using a different mechanism (anti-Siglec-8 antibody lirentelimab), competing for the same severe CRS treatment paradigm that Lyra's LYR-210 aims to serve.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

Lyra Therapeutics social profiles

Digital presence

Lyra Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Lyra Therapeutics leadership team

Management profile

Number of profiles

Profiles11 records

Lyra Therapeutics funding detail

Funding detail

Funding overview

Funding rounds11 records

Investors16 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Lyra Therapeutics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Lyra Therapeutics

What does Lyra Therapeutics do?

Lyra Therapeutics develops bioabsorbable drug-eluting nasal mesh products (LYR-210 and LYR-220) built on its proprietary XTreo™ platform to deliver up to six months of continuous mometasone furoate anti-inflammatory therapy directly to sinonasal tissues. The products are designed for single in-office administration by ENT specialists to treat adult chronic rhinosinusitis (CRS) patients who have either failed current medical management (LYR-210) or have persistent disease after prior sinus surgery (LYR-220).

Is Lyra Therapeutics a public or private company?

Lyra Therapeutics is a public company. It is classified as public and is currently closed.

When was Lyra Therapeutics founded?

Lyra Therapeutics was founded in 2015. It employs 11 to 50 people.

Where is Lyra Therapeutics based?

Lyra Therapeutics is headquartered in Watertown, United States, in the North America region.

How does Lyra Therapeutics make money?

Two revenue lines are on record. Pharmaceutical product sales are the primary driver. The others are NDA submission and commercialization.

Who are Lyra Therapeutics's main competitors?

Direct peers on record are Intersect ENT (Medtronic) and OptiNose. Broad incumbents are GlaxoSmithKline, AstraZeneca and Sanofi / Regeneron. Nemera is listed as an others. Emerging players are Ocular Therapeutix and Allakos.

Does Lyra Therapeutics have an API?

No public API is recorded for Lyra Therapeutics.

What industry is Lyra Therapeutics in?

Lyra Therapeutics's product category is ENT Therapeutics. Its primary akta.pro industry code is HLAHAIAK, Nasal Drug Delivery Devices (Sprays/Powder Devices), with a secondary code of HLAKAMAD, Rhinology & Sinus Surgery. Its NAICS code is 5417 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Ticker ReportHead-To-Head Survey: Chugai Pharmaceutical (OTCMKTS:CHGCY) versus Lyra Therapeutics (OTCMKTS:LYRA)Chugai Pharmaceutical beats Lyra Therapeutics on 12 of 14 factors, including revenue and earnings. Chugai's revenue is $8.41 billion versus Lyra's $600,000, and its analyst rating score is 2.60 versus 1.00. Lyra is more affordable with a lower P/E ratio.American Banking and Market NewsHead to Head Comparison: Lyra Therapeutics (OTCMKTS:LYRA) & Ovid Therapeutics (NASDAQ:OVID)Ovid Therapeutics and Lyra Therapeutics are compared on institutional ownership, analyst ratings, and financial metrics. Ovid has higher revenue ($7.25M vs $400K), a lower P/E ratio, and a consensus price target of $6.00 with 153.16% upside, while Lyra's rating score is 1.00. Ovid beats Lyra on 9 of 13 factors.American Banking and Market NewsContrasting Sonoma Pharmaceuticals (NASDAQ:SNOA) and Lyra Therapeutics (OTCMKTS:LYRA)Sonoma Pharmaceuticals and Lyra Therapeutics are compared on risk, analyst ratings, institutional ownership, earnings, and valuation. Lyra Therapeutics beats Sonoma on 7 of 11 factors, with higher institutional ownership (95.6% vs 1.9%) and lower volatility (beta 0.5 vs 1.3). Sonoma has higher revenue and earnings but a lower price-to-earnings ratio.Markets DailyFinancial Comparison: Lyra Therapeutics (OTCMKTS:LYRA) & Hypermarcas (OTCMKTS:HYPMY)Hypermarcas and Lyra Therapeutics are compared on profitability, valuation, and institutional ownership. Hypermarcas has higher revenue and earnings, while Lyra Therapeutics trades at a lower price-to-earnings ratio. Hypermarcas beats Lyra on 11 of 13 factors.Ticker ReportContrasting Sonoma Pharmaceuticals (NASDAQ:SNOA) & Lyra Therapeutics (OTCMKTS:LYRA)A comparison of Sonoma Pharmaceuticals and Lyra Therapeutics shows Lyra Therapeutics beats Sonoma on 7 of 11 factors. Lyra has 95.6% institutional ownership versus 1.9% for Sonoma, and Sonoma reports higher revenue and earnings. Lyra's beta of 0.5 indicates lower volatility than Sonoma's 1.3.Defense WorldARS Pharmaceuticals (NASDAQ:SPRY) vs. Lyra Therapeutics (OTCMKTS:LYRA) Head to Head ReviewARS Pharmaceuticals beats Lyra Therapeutics on 9 of 14 factors, including analyst ratings and valuation. ARS has a consensus target price of $25.00, implying 512.75% upside, while Lyra's net margin is -7,266.08% versus ARS's -184.24%. ARS also has lower institutional ownership at 68.2% versus Lyra's 95.6%.Markets DailyHead-To-Head Analysis: Gyre Therapeutics (NASDAQ:GYRE) vs. Lyra Therapeutics (OTCMKTS:LYRA)Gyre Therapeutics beats Lyra Therapeutics on 11 of 14 factors, including higher revenue and earnings. Gyre trades at a lower price-to-earnings ratio and has a stronger analyst consensus with a $16 price target implying 115% upside. Lyra's stock is less volatile but has negative net margins.Markets DailyPfizer (NYSE:PFE) & Lyra Therapeutics (OTCMKTS:LYRA) Critical SurveyPfizer and Lyra Therapeutics are compared on revenue, earnings, institutional ownership, and analyst ratings. Pfizer has higher revenue ($62.58B vs $400K) and earnings ($7.77B vs -$28.92M), while Lyra trades at a lower P/E. Pfizer beats Lyra on 12 of 15 factors, with a consensus price target of $28.39.Ticker ReportLyra Therapeutics (NASDAQ:LYRA) Shares Down 5% – Here’s What HappenedLyra Therapeutics (NASDAQ:LYRA) shares dropped 5% to $0.4750 during Wednesday trading, with trading volume falling sharply to 204 shares compared to the average daily volume of 53,314 shares. The stock has a 50-day moving average of $0.61 and a market cap of approximately $843,125. Institutional investors have recently adjusted their positions in the company, with Sabby Management LLC increasing its stake by 37.2% and Bank of America Corp DE lifting its position by 33.7%.FinSMEsLyora Therapeutics Raises $2.5M in Pre-Seed FundingLyora Therapeutics raised $2.5M in pre-seed funding for its genetic medicines targeting inherited retinal diseases. Its lead program LYA-101 treats retinitis pigmentosa caused by PRPF31 variants, and LYA-102 uses CRISPR for Usher Syndrome Type 2. The company appointed Pam Stetkiewicz as CEO.